NO20100301L - Forbedrete brimonidinsammensetninger for behandling av erytem - Google Patents

Forbedrete brimonidinsammensetninger for behandling av erytem

Info

Publication number
NO20100301L
NO20100301L NO20100301A NO20100301A NO20100301L NO 20100301 L NO20100301 L NO 20100301L NO 20100301 A NO20100301 A NO 20100301A NO 20100301 A NO20100301 A NO 20100301A NO 20100301 L NO20100301 L NO 20100301L
Authority
NO
Norway
Prior art keywords
erythema
treatment
improved
brimonidine
compositions
Prior art date
Application number
NO20100301A
Other languages
English (en)
Norwegian (no)
Inventor
Klaus Theobald
Christopher V Powala
Original Assignee
Galderma Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Lab Inc filed Critical Galderma Lab Inc
Publication of NO20100301L publication Critical patent/NO20100301L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20100301A 2007-08-31 2010-03-04 Forbedrete brimonidinsammensetninger for behandling av erytem NO20100301L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96719107P 2007-08-31 2007-08-31
PCT/US2008/010290 WO2009032223A1 (en) 2007-08-31 2008-08-29 Improved brimonidine compositions for treating erythema

Publications (1)

Publication Number Publication Date
NO20100301L true NO20100301L (no) 2010-03-25

Family

ID=40407909

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20100301A NO20100301L (no) 2007-08-31 2010-03-04 Forbedrete brimonidinsammensetninger for behandling av erytem

Country Status (12)

Country Link
US (3) US20090061020A1 (enExample)
EP (1) EP2200617A4 (enExample)
JP (1) JP2010537988A (enExample)
KR (1) KR20100055453A (enExample)
CN (2) CN102552112A (enExample)
AR (1) AR068816A1 (enExample)
AU (1) AU2008296948A1 (enExample)
BR (1) BRPI0816097A2 (enExample)
CA (1) CA2698680A1 (enExample)
MX (1) MX2010002392A (enExample)
NO (1) NO20100301L (enExample)
WO (1) WO2009032223A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US7812049B2 (en) * 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
WO2010136594A2 (en) * 2009-05-29 2010-12-02 Symatese Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
BR112012009891A2 (pt) * 2009-10-26 2015-09-29 Galderma Pharma Sa métodos para tratar eritema agudo e para prevenir o eritema agudo e uma inflamação secundária em um humano em necessidade do mesmo
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
CN106038476B (zh) * 2010-03-26 2020-04-17 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
US8916562B2 (en) 2010-03-26 2014-12-23 Galderma Research & Development Snc Methods and compositions for safe and effective treatment of telangiectasia
PH12013500679A1 (en) * 2010-10-21 2013-06-10 Galderma Sa Topical gel composition
EP2629757A2 (en) * 2010-10-21 2013-08-28 Galderma S.A. Brimonidine gel compositions and methods of use
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
JP6225030B2 (ja) 2011-02-15 2017-11-01 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 酒さの症状を治療するためのオキシメタゾリンの薬学的クリーム組成物
EP2768502A2 (en) 2011-10-19 2014-08-27 Galderma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
UA109359C2 (xx) * 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
FR3000398A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et de brimonidine pour le traitement de la rosacee
FR3000397A1 (fr) 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
FR3015288B1 (fr) 2013-12-19 2016-02-12 Galderma Res & Dev Utilsation du naratriptan dans le traitement de la rosacee
AU2015274532B2 (en) 2014-06-11 2020-06-11 Epi Health, Llc Stabilized oxymetazoline formulations and their uses
EP3651767A1 (en) * 2017-07-14 2020-05-20 Galderma Research & Development Methods and compositions for reducing side effects in chemotherapeutic treatments
EP3962478A1 (en) 2019-05-01 2022-03-09 Clexio Biosciences Ltd. Methods of treating pruritus

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
GB8827968D0 (en) * 1988-11-30 1989-01-05 Boots Co Plc Sunscreen compositions
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
US6410045B1 (en) * 1999-02-22 2002-06-25 Clyde Lewis Schultz Drug delivery system for antiglaucomatous medication
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US20050276765A1 (en) * 2004-06-10 2005-12-15 Paul Nghiem Preventing skin damage
CA2709199A1 (en) * 2007-12-21 2009-07-02 Galderma Laboratories, Inc. Pre-surgical treatment

Also Published As

Publication number Publication date
EP2200617A1 (en) 2010-06-30
US20120282346A1 (en) 2012-11-08
CA2698680A1 (en) 2009-03-12
JP2010537988A (ja) 2010-12-09
KR20100055453A (ko) 2010-05-26
EP2200617A4 (en) 2011-01-12
MX2010002392A (es) 2010-07-28
CN102552112A (zh) 2012-07-11
WO2009032223A1 (en) 2009-03-12
AU2008296948A1 (en) 2009-03-12
AR068816A1 (es) 2009-12-09
US20120040016A1 (en) 2012-02-16
CN101808645A (zh) 2010-08-18
US20090061020A1 (en) 2009-03-05
BRPI0816097A2 (pt) 2016-11-01

Similar Documents

Publication Publication Date Title
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
NO20064584L (no) Tetrahydropyridoindolderivater
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
WO2013173129A3 (en) Treatment of amd using aav sflt-1
NO20073959L (no) Kinazolinderivat, fremgangsmate for fremstilling og anvendelse derav for inhibering av vekst av kreftceller
MA32200B1 (fr) Nouvelles formulations,comprimes comprenant de telles formulations, leur utilisation et leur procede de preparation
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
NO20073059L (no) 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
EA201070477A1 (ru) Транс-кломифен для лечения метаболического синдрома
WO2010011772A3 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
WO2008013987A3 (en) N-alkyl substituted piperazinylmethylquinazolinones and azepanylmethylquinazolinones
AR047993A1 (es) Composicion farmaceutica que comprende pimobendano
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
HK1202448A1 (en) Topical formulation for administering a compound
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
NO20083905L (no) Nye pyron-indol derivater og fremgangsmate for deres fremstilling
MX2011012143A (es) Composiciones adecuadas para el tratamiento topico o infecciones fungicas de la piel y uñas.
MX2010009624A (es) Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1.
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
CY1109537T1 (el) Πεπτιδια και παραγωγα πεπτιδιου, παρασκευη αυτων καθως επισης χρηση αυτων για την παρασκευη θεραπευτικως η/και προληπτικως δραστικης φαρμακευτικης συνθεσης
CY1115961T1 (el) Ανυδρη μορφη κρυσταλλικης μηλεϊνικης ορβεπιταντης (orvepitant maleate)

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application